Trédan O, Provansal M, Abdeddaim C, Lardy-Cleaud A, Hardy-Bessard AC, Kalbacher E, Floquet A, Venat-Bouvet L, Lortholary A, Pop O, Frenel JS, Cancel M, Largillier R, Louvet C, You B, Zannetti A, Anota A, Treilleux I, Pissaloux D, Houlier A, Savoye AM, Mouret-Reynier MA, Meunier J, Levaché CB, Brocard F, and Ray-Coquard I
Objective: To evaluate the efficacy and safety of regorafenib versus tamoxifen in platinum-sensitive ovarian cancer biological recurrence, defined by CA-125 increase without radiological (RECIST criteria) or symptomatic evidence of progression., Patients and Methods: 116 patients with platinum-sensitive ovarian cancer presenting an isolated increase of CA-125 were planned to be randomized. Regorafenib was administered orally at 160 or 120 mg daily, 3 weeks on/1 week off or tamoxifen at 40 mg daily, until disease progression or development of unacceptable toxicity. The primary endpoint was Progression-Free Survival, assessed by progression according to RECIST 1.1 or death (by any cause). Secondary endpoints included Overall Survival, Best Response and CA-125 response rate., Results: 68 patients were randomized. Median age was 67 years (range: 30-87). Primary site of cancer was ovarian for most patients (92.6%). Tumors were predominantly serous / (89.7%), high grade (83.6%) and initial FIGO staging was III for 69.6% of the patients. Most (79.4%) patients were included after the first line of platinum-based treatment. After a median follow-up of 32 months, there was no difference of progression-free survival (PFS) between regorafenib and tamoxifen groups (p = 0.72), with median PFS of 5.6 months (CI 90%: 3.84-7.52) for the tamoxifen arm and 4.6 months (CI 90%: 3.65-7.33) for the regorafenib arm. There was also no difference in term of overall survival, best response or CA-125 response, delay to next therapy. Regorafenib presented a less favorable safety profile than tamoxifen, with grade 3/4 events occurring for 90.9% of the patients compared to 54.3% for tamoxifen. The most frequent were cutaneous, digestive, and biological events. Notably, hand-foot syndrome occurred in 36.4% of these patients., Conclusion: Regorafenib presented an unfavorable toxicity profile compared to tamoxifen, with no superior efficacy in this population of patients., Competing Interests: Declaration of Competing Interest Dr. Trédan reports supports from the present manuscripts to ARCAGY GINECO from Bayer HealthCare, grants or contracts from Roche, BMS and MSD-Merck (payments to his institution), consulting fees from Roche, Pfizer, Astra-Zeneca, Lilly, Novartis-Sandoz, Daiichi-Sankyo, Seagen Pierre Fabre, MSD-Merck, Eisai (payments to him), payments/honoraria from Roche, Pfizer, Astra-Zeneca, Lilly, Novartis-Sandoz, Daiichi-Sankyo, Seagen, Pierre Fabre, MSD-Merck, Eisai, support for attending meeting and/or travel from Roche, Astra-Zeneca, Pfizer (payments to him). Dr. Hardy-Bessard reports payment/honoraria from MSD, Astra-Zeneca, GSK and participation on data safety monitoring board/advisory board with Clovis, MSD, Astra-Zeneca, GSK, Novartis, Pfizer. Dr. Lortholary reports payment/honoraria from Astra-Zeneca, Roche, MSD, Clovis, Novartis, support for attending meetings/travel from Roche and Astra-Zeneca and participation in a Data Safety Monitoring Board/Advisory board with Astra-Zeneca, Roche, MSD, Clovis and Novartis. Dr. Frenel reports payments/honoraria from Astra Zeneca, Lilly, Daiichi, Pfizer, Amgen, support for attending meetings/travel from Pfizer and Astra Zeneca, and participation on a Data Safety Monitoring Board/advisory board from Pfizer, Lilly, Novartis, GSK, Astra-Zeneca, MSD, Roche and Clovis. Dr. Louvet reports payments/honoraria from Merck, Roche, Servier and Amgen and support for attending meetings/travels from Roche and Merck. Dr. You reports consulting fees from MSD, Astra-Zeneca, GSK, Bayer, Roche, ECS Progastrine, Novartis, LEK, Amgen, Clovis, Merck Serono, BMS, Seagen. Amélie Anota reports consulting fees from Roche, Astra-Zeneca, Sandoz, Pfizer/Hospira, payment or honoraria for lectures from Astra-Zeneca and BMS and support for attending meetings/travels from Roche, Astra-Zeneca and Novartis. Pr Ray-Coquard reports consulting fees from Amgen, Astra-Zeneca, Clovis Oncology, Genmab, GSK, ImmunoGen, Merck Sharp & Dohme, Pfizer/Merck-Sereno, PharmaMar, and Roche, grants/contracts with Roche, BMS, MSD, GSK Company and support for attending meetings/travels from Astra-Zeneca, Roche, GSK and Clovis. The remaining authors declare no conflict of interest., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)